Access DB# 154102

SEARCH REQUEST FORM

Scientific and Technical Information Center

Requester's Full Name: BEN SACKEY Examiner #: 73489 Date: 5/25/05
Art Unit: 1626 Phone Number ~~30~~ 2-0704 Serial Number: 10/803,607
Mail Box and Bldg/Room Location: REM 5-635 Results Format Preferred (circle): PAPER DISK E-MAIL

If more than one search is submitted, please prioritize searches in order of need.

****

Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc, if known. Please attach a copy of the cover sheet, pertinent claims, and abstract.

Title of Invention: Novel Compounds for modulating cell proliferation

Inventors (please provide full names): Roifman et al

Earliest Priority Filing Date: _____

**For Sequence Searches Only* Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.*

Compounds of Structural formula (I)



****

STAFF USE ONLY	Type of Search	Vendors and cost where applicable
Searcher: R. Fuller	NA Sequence (#)_____	STN ✓
Searcher Phone #: _____	AA Sequence (#)_____	Dialog _____
Searcher Location: _____	Structure (#) 1	Questel/Orbit _____
Date Searcher Picked Up: _____	Bibliographic _____	Dr.Link _____
Date Completed: 5/26/05	Litigation _____	Lexis/Nexis _____
Searcher Prep & Review Time: 30	Fulltext _____	Sequence Systems _____
Clerical Prep Time: _____	Patent Family _____	WWW/Internet _____
Online Time: 20	Other _____	Other (specify) _____

PTO-1590 (8-01)

STIC Search Report
EIC 1700

STIC Database Tracking Number: 154102

TO: Ben Sackey **Location: REM 5B35** **Art Unit : 1626** **May 26, 2005** **Case Serial Number: 10/803607**	**From: Kathleen Fuller** **Location: EIC 1700** **REMSEN 4B28** **Phone: 571/272-2505** **Kathleen.Fuller@uspto.gov**

Search Notes

=> FILE REG
FILE 'REGISTRY' ENTERED AT 15:47:48 ON 26 MAY 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 25 MAY 2005 HIGHEST RN 851163-60-5
DICTIONARY FILE UPDATES: 25 MAY 2005 HIGHEST RN 851163-60-5

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 18, 2005

Please note that search-term pricing does apply when conducting SmartSELECT searches.

****
*
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
*
****

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=> FILE HCAPLU
FILE 'HCAPLUS' ENTERED AT 15:47:52 ON 26 MAY 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 26 May 2005 VOL 142 ISS 22
FILE LAST UPDATED: 25 May 2005 (20050525/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

KATHLEEN FULLER EIC 1700 REMSON 4B28 571/272-2505

=> D QUE
L38 STR





424 structures from query

VAR G1=14/17/NH2/NH/P/22
VAR G2=S/N/O
VAR G3=NH2/OH/NH/AK/O/HY
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RSPEC I
NUMBER OF NODES IS 24

STEREO ATTRIBUTES: NONE

L40	424	SEA FILE=REGISTRY SSS FUL L38
L41	249	SEA FILE=HCAPLUS ABB=ON L40
L42	5	SEA FILE=HCAPLUS ABB=ON L41 AND CELL(2A)PROLIF?
L43	8	SEA FILE=HCAPLUS ABB=ON L41 AND (CANCER? OR ANTITUMOR? OR NEOPLAS?)
L44	1	SEA FILE=HCAPLUS ABB=ON L41 AND PHARMACE?/SC
L45	1	SEA FILE=HCAPLUS ABB=ON L41 AND PHARMACE?/SC,SC
L46	9	SEA FILE=HCAPLUS ABB=ON L41(L)THU/RL
L47	11	SEA FILE=HCAPLUS ABB=ON (L42 OR L43 OR L44 OR L45 OR L46)

11 CA references with ulcers

=> D L47 BIB ABS HITIND HITSTR 1-11

L47 ANSWER 1 OF 11 HCAPLUS COPYRIGHT 2005 ACS on STN
AN 2005:120874 HCAPLUS
DN 142:197698
TI Preparation of arylcyanopentadienoates as modulators of **cell proliferation**
IN Roifman, Chaim M.; Demin, Peter; Rounova, Olga; Grunberger, Thomas; Cimpean, Octavian Laurand
PA The Hospital for Sick Children, Can.
SO PCT Int. Appl., 46 pp.
CODEN: PIXXD2
DT Patent

applicants

LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005012234	A1	20050210	WO 2004-CA1431	20040730

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI US 2003-491109P P 20030730
OS MARPAT 142:197698
GI



I

AB Title compds. [I; Q = CO2XR4, SO2R5; R1, R2, R3 = H, OH, alkyl, alkoxy, alkylcarbonyloxy, amino, alkylcarbonylamino, SH, alkylthio, NO2, CF2, OCF3, halo, etc.; R4 = (substituted) aryl; R5 = alkyl, (substituted) Ph, pyridyl; X = (CH2CH2O)n, (CH2)n; n = 1-4; with provisos], were prepared Thus, 2-(4-chlorobenzenesulfonyl)-5-(3,4-dihydroxyphenyl)penta-2E,4E-dienenitrile (CRVIII-51) (preparation via Knoevenagel reaction outlined) killed Z119 acute lymphoblastic leukemia cells with IC50 = 0.23 μM.

IC ICM C07C255-41
ICS C07C255-38; C07C255-32; C07D213-71; A61P035-00; A61K032-77; A61K031-4402

CC 25-20 (Benzene, Its Derivatives, and Condensed Benzenoid Compounds)
Section cross-reference(s): 1, 63

ST arylcyanopentadienoate prepn **cell proliferation** modulator; anticancer cyanopentadienoate aryl prepn

IT **Cell proliferation**
(modulators; preparation of arylcyanopentadienoates as modulators of **cell proliferation**)

IT **Antitumor** agents
Drug delivery systems
Human
(preparation of arylcyanopentadienoates as modulators of **cell proliferation**)

IT Hematopoietic precursor **cell**
(**proliferation** inhibitors; preparation of arylcyanopentadienoates as modulators of **cell proliferation**)

IT **Neoplasm**
(treatment; preparation of arylcyanopentadienoates as modulators of **cell proliferation**)

IT **569343-54-0P 569343-56-2P 569343-58-4P**
569343-63-1P 569343-66-4P 569343-72-2P 569343-75-5P

569343-78-8P 569343-80-2P 569343-82-4P 569343-88-0P 569343-91-5P
838853-66-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)
(claimed compound; preparation of arylcyanopentadienoates as modulators of **cell proliferation**)

IT 100-51-6, Benzyl alcohol, reactions 112-35-6, 2-[2-(2-Methoxyethoxy)ethoxy]ethanol 372-09-8, Cyanoacetic acid 1734-79-8, 4-Nitrocinnamaldehyde 109032-31-7
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of arylcyanopentadienoates as modulators of **cell proliferation**)

IT 14447-18-8P, Benzyl cyanoacetate 68149-78-0P, 3,4-Dihydroxycinnamaldehyde 315178-31-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of arylcyanopentadienoates as modulators of **cell proliferation**)

IT **569343-54-0P 569343-56-2P 569343-58-4P 569343-63-1P 569343-66-4P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)
(claimed compound; preparation of arylcyanopentadienoates as modulators of **cell proliferation**)

RN 569343-54-0 HCAPLUS
CN 2,4-Pentadienoic acid, 2-cyano-5-(4-hydroxy-3,5-dimethoxyphenyl)-, phenylmethyl ester, (2E,4E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 569343-56-2 HCAPLUS
CN 2,4-Pentadienoic acid, 2-cyano-5-(3,4-dihydroxyphenyl)-, phenylmethyl ester, (2E,4E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 569343-58-4 HCAPLUS
CN 2,4-Pentadienoic acid, 2-cyano-5-(3,4-dihydroxyphenyl)-,

2-[2-(2-methoxyethoxy)ethoxy]ethyl ester, (2E,4E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 569343-63-1 HCAPLUS
CN 2,4-Pentadienoic acid, 2-cyano-5-(4-hydroxy-3,5-dimethoxyphenyl)-, 2-[2-(2-methoxyethoxy)ethoxy]ethyl ester, (2E,4E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 569343-66-4 HCAPLUS
CN 2,4-Pentadienoic acid, 2-cyano-5-(4-hydroxy-3-methoxyphenyl)-, phenylmethyl ester, (2E,4E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L47 ANSWER 2 OF 11 HCAPLUS COPYRIGHT 2005 ACS on STN
AN 2004:406958 HCAPLUS
DN 141:116436
TI Tyrenes: synthesis of new antiproliferative compounds with an extended conjugation
AU Demin, Peter; Rounova, Olga; Grunberger, Thomas; Cimpean, Lorand; Sharfe, Nigel; Roifman, Chaim M.
CS Research Institute, Division of Immunology and Allergy, Infection, Immunity, Injury and Repair Program, The Hospital for Sick Children and University of Toronto, Toronto, M5G 1X8, Can.
SO Bioorganic & Medicinal Chemistry (2004), 12(11), 3019-3026
CODEN: BMECEP; ISSN: 0968-0896

PB Elsevier Ltd.
DT Journal
LA English
OS CASREACT 141:116436
AB A series of substituted styryl-acrylonitriles was designed and synthesized. The new compds., called tyrenes, were tested for the ability to inhibit acute lymphocytic leukemia (ALL) **cancer** cell growth, as well as on their toxicity to normal bone marrow (NBM) cells. The results showed that 3,4-dihydroxystyryl-acrylonitriles, in particular CR-4, revealed great potency as **antitumor** agents, and also exhibited low toxicity to normal cells. The effectiveness of these compds. with extended conjugation may be due to their possible functioning as reactive Michael acceptors.
CC 1-3 (Pharmacology)
Section cross-reference(s): 25
ST tyrene antiproliferative **antitumor** acute lymphocytic leukemia
IT **Antitumor** agents
Bone marrow
Human
(synthesis of new antiproliferative compds., tyrenes, with extended conjugation)
IT **368836-72-0P**
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(synthesis of new antiproliferative compds., tyrenes, with extended conjugation)
IT **368836-70-8P 368836-71-9P 368836-76-4P**
368836-78-6P 368836-79-7P 368836-92-4P
510728-40-2P 721923-86-0P 721923-87-1P
721923-88-2P 721923-89-3P 721923-90-6P
721923-91-7P
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)
(synthesis of new antiproliferative compds., tyrenes, with extended conjugation)
IT **368836-72-0P**
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(synthesis of new antiproliferative compds., tyrenes, with extended conjugation)
RN 368836-72-0 HCAPLUS
CN 2,4-Pentadienamide, 2-cyano-5-(3,4-dihydroxyphenyl)-N-(phenylmethyl)-, (2E,4E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



IT **368836-70-8P 368836-71-9P 368836-76-4P**
368836-78-6P 368836-79-7P 368836-92-4P
510728-40-2P 721923-86-0P 721923-88-2P
721923-89-3P 721923-90-6P 721923-91-7P
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)
(synthesis of new antiproliferative compds., tyrenes, with extended conjugation)

RN 368836-70-8 HCAPLUS
CN 2,4-Pentadienamide, 2-cyano-N-[(3,4-dihydroxyphenyl)methyl]-5-(4-hydroxy-3,5-dimethoxyphenyl)-, (2E,4E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 368836-71-9 HCAPLUS
CN 2,4-Pentadienamide, 2-cyano-5-(3,4-dimethoxyphenyl)-N-(phenylmethyl)-, (2E,4E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 368836-76-4 HCAPLUS
CN 2,4-Pentadienamide, 2-cyano-N-[(3,4-dihydroxyphenyl)methyl]-5-phenyl-, (2E,4E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 368836-78-6 HCAPLUS
CN 2,4-Pentadienamide, 2-cyano-5-(3,4-dihydroxyphenyl)-N-[(3,4-

dihydroxyphenyl)methyl]-, (2E,4E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 368836-79-7 HCAPLUS
CN 2,4-Pentadienamide, 2-cyano-5-phenyl-N-(phenylmethyl)-, (2E,4E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 368836-92-4 HCAPLUS
CN 2,4-Pentadienamide, 2-cyano-N-[(3,4-dihydroxyphenyl)methyl]-5-(4-nitrophenyl)-, (2E,4E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 510728-40-2 HCAPLUS
CN 2,4-Pentadienamide, 2-cyano-5-(4-hydroxy-3-methoxyphenyl)-N-(phenylmethyl)-, (2E,4E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 721923-86-0 HCAPLUS

CN 2,4-Pentadienamide, 2-cyano-5-(3,4-dihydroxyphenyl)-N-[(3,4-dimethoxyphenyl)methyl]-, (2E,4E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 721923-88-2 HCAPLUS
CN 2,4-Pentadienamide, 2-cyano-N-[(3,4-dihydroxyphenyl)methyl]-5-(4-hydroxy-3-methoxyphenyl)-, (2E,4E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 721923-89-3 HCAPLUS
CN 2,4-Pentadienamide, 2-cyano-5-(3,4-dihydroxyphenyl)-N-[[3-(trifluoromethyl)phenyl]methyl]-, (2E,4E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 721923-90-6 HCAPLUS
CN 2,4-Pentadienamide, 2-cyano-5-(3,4-dihydroxyphenyl)-N-[(3-fluorophenyl)methyl]-, (2E,4E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 721923-91-7 HCAPLUS
CN 2,4-Pentadienamide, 2-cyano-5-(3,4-dihydroxyphenyl)-N-(4-pyridinylmethyl)-, (2E,4E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RE.CNT 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L47 ANSWER 3 OF 11 HCAPLUS COPYRIGHT 2005 ACS on STN
AN 2004:331967 HCAPLUS
DN 140:332499
TI Styrylacrylonitrile compounds, and preparation thereof, for the inhibition of vascular endothelial growth factor
IN Roifman, Chaim M.; Simon, Amos J.; Demin, Peter M.; Rounova, Olga B.
PA The Hospital for Sick Children, Can.
SO PCT Int. Appl., 80 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004032911	A2	20040422	WO 2003-CA1558	20031010
	WO 2004032911	A3	20040617		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2407755	AA	20040411	CA 2002-2407755	20021011
PRAI	CA 2002-2407755	A	20021011		

US 2002-417642P P 20021011
OS MARPAT 140:332499
AB The invention discloses therapeutic styrylacrylonitrile compds. and inhibition of secretion of vascular endothelial grown factor (VEGF) and its effects, including angiogenesis. Preparation and biol. activity of e.g. (E,E)-2-(benzylaminocarbonyl)-3-(3,4-dihydroxystyryl)acrylonitrile are included.
IC ICM A61K031-165
ICS A61K031-216; A61K031-137; A61K031-277; A61K031-662; A61P035-00; A61P035-02; A61P037-06; A61P031-22; A61P027-02; A61P019-08; A61P017-00
CC 1-8 (Pharmacology)
IT Bone, **neoplasm**
(Ewing's sarcoma; styrylacrylonitrile compds., and preparation thereof, for VEGF inhibition)
IT Mammary gland, **neoplasm**
(Paget's disease; styrylacrylonitrile compds., and preparation thereof, for VEGF inhibition)
IT Blood vessel, **neoplasm**
(angiofibroma; styrylacrylonitrile compds., and preparation thereof, for VEGF inhibition)
IT **Neoplasm**
(ascites associated with; styrylacrylonitrile compds., and preparation thereof, for VEGF inhibition)
IT **Neoplasm**
(blood-borne; styrylacrylonitrile compds., and preparation thereof, for VEGF inhibition)
IT Intestine, **neoplasm**
(colon; styrylacrylonitrile compds., and preparation thereof, for VEGF inhibition)
IT Brain, **neoplasm**
(edema associated with; styrylacrylonitrile compds., and preparation thereof, for VEGF inhibition)
IT Blood vessel, **neoplasm**
(hemangioma; styrylacrylonitrile compds., and preparation thereof, for VEGF inhibition)
IT **Neoplasm**
(hematol.; styrylacrylonitrile compds., and preparation thereof, for VEGF inhibition)
IT Nervous system, **neoplasm**
(meningioma; styrylacrylonitrile compds., and preparation thereof, for VEGF inhibition)
IT **Neoplasm**
(metastasis; styrylacrylonitrile compds., and preparation thereof, for VEGF inhibition)
IT Meninges
(**neoplasm**, meningioma; styrylacrylonitrile compds., and preparation thereof, for VEGF inhibition)
IT Nerve, **neoplasm**
(neuroblastoma; styrylacrylonitrile compds., and preparation thereof, for VEGF inhibition)
IT Bone, **neoplasm**
Sarcoma
(osteosarcoma; styrylacrylonitrile compds., and preparation thereof, for VEGF inhibition)
IT Skin, **neoplasm**
(pseudoxanthoma elasticum; styrylacrylonitrile compds., and preparation thereof, for VEGF inhibition)

IT Eye, **neoplasm**
(retinoblastoma; styrylacrylonitrile compds., and preparation thereof, for VEGF inhibition)
IT **Neoplasm**
(solid; styrylacrylonitrile compds., and preparation thereof, for VEGF inhibition)
IT AIDS (disease)
Angiogenesis
Angiogenesis inhibitors
Anti-AIDS agents
Anti-inflammatory agents
Antiarthritics
Antidiabetic agents
Antirheumatic agents
Antitumor agents
Antiulcer agents
Arthritis
Atherosclerosis
Behcet's syndrome
Brain, **neoplasm**
Burn
Cardiovascular agents
Cell migration
Cell proliferation
Cytotoxic agents
Dermatitis
Diabetes mellitus
Drug delivery systems
Human
Inflammation
Injury
Intraocular lenses
Leukemia
Lyme disease
Lymphoproliferative disorders
Mammary gland, **neoplasm**
Medical goods
Melanoma
Myeloproliferative disorders
Neoplasm
Osteoarthritis
Pancreas, **neoplasm**
Preeclampsia
Prostate gland, **neoplasm**
Psoriasis
Rheumatoid arthritis
Sarcoidosis
Sickle cell anemia
Sjogren's syndrome
Syphilis
Transplant rejection
Transplant rejection
Ulcer
Wound healing promoters
(styrylacrylonitrile compds., and preparation thereof, for VEGF inhibition)
IT **368836-71-9P**
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(styrylacrylonitrile compds., and preparation thereof, for VEGF inhibition)

IT **368836-70-8P 368836-72-0P 368836-75-3P 368836-76-4P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)
(styrylacrylonitrile compds., and preparation thereof, for VEGF inhibition)

IT **368836-71-9P**
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(styrylacrylonitrile compds., and preparation thereof, for VEGF inhibition)

RN 368836-71-9 HCAPLUS
CN 2,4-Pentadienamide, 2-cyano-5-(3,4-dimethoxyphenyl)-N-(phenylmethyl)-, (2E,4E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



IT **368836-70-8P 368836-72-0P 368836-75-3P 368836-76-4P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)
(styrylacrylonitrile compds., and preparation thereof, for VEGF inhibition)

RN 368836-70-8 HCAPLUS
CN 2,4-Pentadienamide, 2-cyano-N-[(3,4-dihydroxyphenyl)methyl]-5-(4-hydroxy-3,5-dimethoxyphenyl)-, (2E,4E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 368836-72-0 HCAPLUS
CN 2,4-Pentadienamide, 2-cyano-5-(3,4-dihydroxyphenyl)-N-(phenylmethyl)-, (2E,4E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 368836-75-3 HCAPLUS
CN 2,4-Pentadienamide, 5-[3,4-bis[[(1,1-dimethylethyl)dimethylsilyl]oxy]phenyl]-2-cyano-N-(phenylmethyl)-, (2E,4E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 368836-76-4 HCAPLUS
CN 2,4-Pentadienamide, 2-cyano-N-[(3,4-dihydroxyphenyl)methyl]-5-phenyl-, (2E,4E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L47 ANSWER 4 OF 11 HCAPLUS COPYRIGHT 2005 ACS on STN
AN 2003:952620 HCAPLUS
DN 140:246350
TI Inhibition of acute lymphoblastic and myeloid leukemias by a novel kinase inhibitor
AU Grunberger, Thomas; Demin, Peter; Rounova, Olga; Sharfe, Nigel; Cimpean, Lorand; Dadi, Harjit; Freywald, Andrew; Estrov, Zeev; Roifman, Chaim M.
CS Division of Immunology and Allergy, Department of Pediatrics, Infection, Immunity, Injury, and Repair Program, Research Institute, The Hospital for Sick Children and the University of Toronto, Toronto, ON, Can.
SO Blood (2003), 102(12), 4153-4158
CODEN: BLOOAW; ISSN: 0006-4971
PB American Society of Hematology
DT Journal
LA English

AB In recent years, synthetic tyrosine kinase inhibitors have made a rapid transition from basic research to therapeutic application. These compds. represent a major clin. advance in the approach to **cancer** in their relative specificity of action and decreased toxicity. We report here the effects of a novel tyrosine kinase inhibitor CR4 that interferes with growth-promoting pathways to markedly inhibit the growth and survival of both Philadelphia-pos. and -neg. acute lymphoblastic leukemia (ALL) as well as acute myeloid leukemia (AML). While efficiently ablating leukemic cell growth, normal cell growth and differentiation remain unaffected by CR4. CR4 demonstrates an ability to inhibit the function of multiple growth-critical kinases and yet exhibits a low level of cytotoxicity. These findings suggest that CR4 may prove to be highly effective as a therapeutic agent.

CC 1-6 (Pharmacology)

ST protein tyrosine kinase inhibitor CR4 **antitumor** lymphoblast myeloid leukemia; hydroxystyryl acrylonitrile compd tyrosine kinase **antitumor** lymphoblast myeloid leukemia

IT **368836-72-0**
RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(inhibition of acute lymphoblastic and myeloid leukemias by a novel kinase inhibitor CR4)

IT **368836-72-0**
RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(inhibition of acute lymphoblastic and myeloid leukemias by a novel kinase inhibitor CR4)

RN 368836-72-0 HCAPLUS

CN 2,4-Pentadienamide, 2-cyano-5-(3,4-dihydroxyphenyl)-N-(phenylmethyl)-, (2E,4E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RE.CNT 48 THERE ARE 48 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L47 ANSWER 5 OF 11 HCAPLUS COPYRIGHT 2005 ACS on STN

AN 2003:591138 HCAPLUS

DN 139:133348

TI Preparation of arylpentadienoates for modulating **cell proliferation**

IN Roifman, Chaim M.; Demin, Peter; Grunberger, Thomas; Rounova, Olga; Cimpean, Octavian Laurand

PA The Hospital for Sick Children, Can.

SO PCT Int. Appl., 46 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

PI WO 2003062190 A1 20030731 WO 2003-CA32 20030117
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
CA 2473763 AA 20030731 CA 2003-2473763 20030117
EP 1467967 A1 20041020 EP 2003-700255 20030117
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
BR 2003007000 A 20041103 BR 2003-7000 20030117
GB 2401363 A1 20041110 GB 2004-18331 20030117
US 2005085538 A1 20050421 US 2003-501699 20030117
PRAI US 2002-349214P P 20020118
US 2002-349215P P 20020118
US 2002-349216P P 20020118
WO 2003-CA32 W 20030117
OS MARPAT 139:133348
GI



I



II

AB Title compds. I and II [R1-R3 = H, OH, alkyl, alkoxy, (un)substituted NH2, SH, alkylthio, NO2, CF3, OCF3, halo; R4 = (un)substituted aryl; X = (CH2CH2O)n, (CH2)n; n = 1-4] were prepared Thus, 3,4-(Me3CMe2SiO)2C6H3CH:CHCH2OH was oxidized and desilylated to give caffeoylaldehyde which was treated with benzyl cyanoacetate to give I [R1, R2 = OH, X = CH2, R3 = H, R4 = Ph] which had IC50 for inhibition of AML-3 acute myeloid leukemia in vitro of 0.09 μM.

IC ICM C07C255-41
ICS C07C309-73; A61K031-165

CC 25-18 (Benzene, Its Derivatives, and Condensed Benzenoid Compounds)

Section cross-reference(s): 1

IT Leukemia
(acute lymphocytic; preparation of arylpentadienoates for modulating **cell proliferation**)

IT Leukemia
(acute myelogenous; preparation of arylpentadienoates for modulating **cell proliferation**)

IT **Antitumor** agents
Cell proliferation
Human
Neoplasm
(preparation of arylpentadienoates for modulating **cell proliferation**)

IT **569343-54-0P 569343-56-2P 569343-58-4P**
569343-63-1P 569343-72-2P 569343-75-5P 569343-78-8P
569343-80-2P 569343-82-4P 569343-88-0P 569343-91-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of arylpentadienoates for modulating **cell proliferation**)

IT 112-35-6, 2-[2-(2-Methoxyethoxy)ethoxy)ethanol 372-09-8, Cyanoacetic acid 109032-31-7
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of arylpentadienoates for modulating **cell proliferation**)

IT 14447-18-8P, Benzyl cyanoacetate 68149-78-0P, Caffeoylaldehyde 315178-31-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of arylpentadienoates for modulating **cell proliferation**)

IT **569343-66-4P**
RL: SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of arylpentadienoates for modulating **cell proliferation**)

IT **569343-54-0P 569343-56-2P 569343-58-4P**
569343-63-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of arylpentadienoates for modulating **cell proliferation**)

RN 569343-54-0 HCAPLUS

CN 2,4-Pentadienoic acid, 2-cyano-5-(4-hydroxy-3,5-dimethoxyphenyl)-, phenylmethyl ester, (2E,4E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 569343-56-2 HCAPLUS
CN 2,4-Pentadienoic acid, 2-cyano-5-(3,4-dihydroxyphenyl)-, phenylmethyl ester, (2E,4E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 569343-58-4 HCAPLUS
CN 2,4-Pentadienoic acid, 2-cyano-5-(3,4-dihydroxyphenyl)-, 2-[2-(2-methoxyethoxy)ethoxy]ethyl ester, (2E,4E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 569343-63-1 HCAPLUS
CN 2,4-Pentadienoic acid, 2-cyano-5-(4-hydroxy-3,5-dimethoxyphenyl)-, 2-[2-(2-methoxyethoxy)ethoxy]ethyl ester, (2E,4E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



IT **569343-66-4P**
RL: SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of arylpentadienoates for modulating **cell proliferation**)
RN 569343-66-4 HCAPLUS
CN 2,4-Pentadienoic acid, 2-cyano-5-(4-hydroxy-3-methoxyphenyl)-, phenylmethyl ester, (2E,4E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L47 ANSWER 6 OF 11 HCAPLUS COPYRIGHT 2005 ACS on STN
AN 2003:300883 HCAPLUS
DN 138:297649
TI Styryl acrylonitrile compounds, their preparation, and their use to promote myelopoiesis
IN Roifman, Chaim M.; Grunberger, Thomas; Sharfe, Nigel; Rounova, Olga B.; Demin, Peter M.; Freywald, Andrew
PA The Hospital for Sick Children, Can.
SO PCT Int. Appl., 56 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003030895	A1	20030417	WO 2002-CA1548	20021011
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2463133	AA	20030417	CA 2002-2463133	20021011
	EP 1453500	A1	20040908	EP 2002-767023	20021011
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
	US 2005014690	A1	20050120	US 2004-492251	20040913
PRAI	US 2001-329168P	P	20011011		
	WO 2002-CA1548	W	20021011		

AB The invention discloses the use of styryl acrylonitrile compds. to promote myelopoiesis. The compds. may be used to treat a subject suffering from neutropenia and other conditions which would benefit from increased myelopoiesis. Moreover, the compds. may be used to treat hematopoietic cells ex-vivo to promote myelopoiesis and therefore may be used advantageously in bone marrow or peripheral blood stem cell transplant.
IC ICM A61K031-277
ICS A61P015-06
CC 1-7 (Pharmacology)
Section cross-reference(s): 25
IT **Neoplasm**
(neutropenia secondary to malignancy; styryl acrylonitrile compound preparation and use to promote myelopoiesis)
IT **368836-71-9P 368836-75-3P**

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(styryl acrylonitrile compound preparation and use to promote myelopoiesis)

IT **368836-70-8P 368836-72-0P 368836-76-4P**
368836-82-2P 510728-39-9P **510728-40-2P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)
(styryl acrylonitrile compound preparation and use to promote myelopoiesis)

IT **368836-71-9P 368836-75-3P**
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(styryl acrylonitrile compound preparation and use to promote myelopoiesis)

RN 368836-71-9 HCAPLUS
CN 2,4-Pentadienamide, 2-cyano-5-(3,4-dimethoxyphenyl)-N-(phenylmethyl)-, (2E,4E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 368836-75-3 HCAPLUS
CN 2,4-Pentadienamide, 5-[3,4-bis[[(1,1-dimethylethyl)dimethylsilyl]oxy]phenyl]-2-cyano-N-(phenylmethyl)-, (2E,4E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



IT **368836-70-8P 368836-72-0P 368836-76-4P**
368836-82-2P 510728-40-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)
(styryl acrylonitrile compound preparation and use to promote myelopoiesis)

RN 368836-70-8 HCAPLUS
CN 2,4-Pentadienamide, 2-cyano-N-[(3,4-dihydroxyphenyl)methyl]-5-(4-hydroxy-3,5-dimethoxyphenyl)-, (2E,4E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 368836-72-0 HCAPLUS
CN 2,4-Pentadienamide, 2-cyano-5-(3,4-dihydroxyphenyl)-N-(phenylmethyl)-, (2E,4E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 368836-76-4 HCAPLUS
CN 2,4-Pentadienamide, 2-cyano-N-[(3,4-dihydroxyphenyl)methyl]-5-phenyl-, (2E,4E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 368836-82-2 HCAPLUS
CN 2,4-Pentadienamide, 2-cyano-5-(4-hydroxy-3,5-dimethoxyphenyl)-N-(2-phenylethyl)-, (2E,4E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 510728-40-2 HCAPLUS

CN 2,4-Pentadienamide, 2-cyano-5-(4-hydroxy-3-methoxyphenyl)-N-(phenylmethyl)-, (2E,4E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L47 ANSWER 7 OF 11 HCAPLUS COPYRIGHT 2005 ACS on STN
AN 2001:780841 HCAPLUS
DN 135:318329
TI Novel compounds for modulating **cell proliferation**
IN Roifman, Chaim M.; Grunberger, Thomas; Rounova, Olga; Demin, Peter; Sharfe, Nigel
PA Hsc Research and Development Limited Partnership, Can.
SO PCT Int. Appl., 100 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001079158	A2	20011025	WO 2001-CA516	20010412
	WO 2001079158	A3	20020131		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2406160	AA	20011025	CA 2001-2406160	20010412
	EP 1272457	A2	20030108	EP 2001-921087	20010412
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	GB 2378948	A1	20030226	GB 2002-26316	20010412
	GB 2378948	B2	20041110		
	US 2003109502	A1	20030612	US 2001-834728	20010412
	US 6800659	B2	20041005		
	JP 2003531133	T2	20031021	JP 2001-576760	20010412
	BR 2001010087	A	20040217	BR 2001-10087	20010412
	US 2004072803	A1	20040415	US 2003-240740	20031027
	US 2004209845	A1	20041021	US 2004-803607	20040317
PRAI	US 2000-196936P	P	20000413		
	US 2001-834728	A1	20010412		
	WO 2001-CA516	W	20010412		

OS MARPAT 135:318329
AB Novel styrylacrylonitrile compds. which are useful in treating a variety of **cell proliferative** disorders such as **cancer**

are disclosed. Thus, (E,E)-2-(benzylaminocarbonyl)-3-(3,4-dimethoxystyryl)acrylonitrile, prepared in 62% yield by condensation of 3,4-dimethoxycinnamaldehyde with N-(cyanoacetyl)benzylamine, was demethylated with BBr3 to give 55% (E,E)-2-(benzylaminocarbonyl)-3-(3,4-dihydroxystyryl)acrylonitrile, useful in treating a variety of **cell proliferative** disorders. Approx. 30 other styrylacrylonitriles were similarly prepared

IC ICM C07C255-00

CC 25-19 (Benzene, Its Derivatives, and Condensed Benzenoid Compounds)
Section cross-reference(s): 1

IT **Antitumor** agents
Cell proliferation
Proliferation inhibition
(preparation of styrylacrylonitriles useful in treating a variety of **cell proliferative** disorders such as **cancer**)

IT **368836-70-8P 368836-72-0P 368836-76-4P**
368836-78-6P 368836-89-9P 368836-90-2P
368836-91-3P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation of styrylacrylonitriles useful in treating a variety of **cell proliferative** disorders such as **cancer**)

IT 64-04-0, Benzeneethanamine 100-46-9, Benzylamine, reactions 104-55-2, Cinnamaldehyde 105-34-0, Methyl cyanoacetate 107-91-5, Cyanoacetamide 141-43-5, 2-Ethanolamine, reactions 331-39-5, 3,4-Dihydroxycinnamic acid 372-09-8, Cyanoacetic acid 868-54-2, 2-Amino-1-propene-1,1,3-tricarbonitrile 1734-79-8, 4-Nitrocinnamaldehyde 2316-26-9, 3,4-Dimethoxycinnamic acid 5763-61-1, 3,4-Dimethoxybenzylamine 7357-70-2, Cyanothioacetamide 18162-48-6, tert-Butylchlorodimethylsilane 36250-64-3, Phenylpropylamine 87345-53-7, 3,5-Dimethoxy-4-hydroxycinnamaldehyde 328384-64-1 368836-69-5
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of styrylacrylonitriles useful in treating a variety of **cell proliferative** disorders such as **cancer**)

IT 3843-74-1P, Methyl 3,4-dihydroxycinnamate 4497-40-9P, 3,4-Dimethoxycinnamaldehyde 5396-64-5P, Methyl 3,4-dimethoxycinnamate 10412-93-8P, N-(2-Cyanoacetyl)benzylamine 15029-40-0P 18523-76-7P, 3,4-Dimethoxycinnamyl alcohol 51838-02-9P 133550-33-1P 244293-59-2P **368836-71-9P** 368836-73-1P 368836-74-2P **368836-75-3P**
368836-77-5P 368836-88-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of styrylacrylonitriles useful in treating a variety of **cell proliferative** disorders such as **cancer**)

IT **368836-79-7P 368836-80-0P 368836-81-1P**
368836-82-2P 368836-83-3P 368836-84-4P
368836-85-5P 368836-86-6P 368836-87-7P
368836-92-4P 368836-93-5P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of styrylacrylonitriles useful in treating a variety of **cell proliferative** disorders such as **cancer**)

IT **368836-70-8P 368836-72-0P 368836-76-4P**
368836-78-6P 368836-89-9P 368836-90-2P
368836-91-3P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation of styrylacrylonitriles useful in treating a variety of **cell proliferative** disorders such as **cancer**
)

RN 368836-70-8 HCAPLUS
CN 2,4-Pentadienamide, 2-cyano-N-[(3,4-dihydroxyphenyl)methyl]-5-(4-hydroxy-3,5-dimethoxyphenyl)-, (2E,4E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 368836-72-0 HCAPLUS
CN 2,4-Pentadienamide, 2-cyano-5-(3,4-dihydroxyphenyl)-N-(phenylmethyl)-, (2E,4E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 368836-76-4 HCAPLUS
CN 2,4-Pentadienamide, 2-cyano-N-[(3,4-dihydroxyphenyl)methyl]-5-phenyl-, (2E,4E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 368836-78-6 HCAPLUS
CN 2,4-Pentadienamide, 2-cyano-5-(3,4-dihydroxyphenyl)-N-[(3,4-dihydroxyphenyl)methyl]-, (2E,4E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 368836-89-9 HCAPLUS
CN 2,4-Pentadienamide, 2-cyano-5-(3,4-dihydroxyphenyl)-, (2E,4E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 368836-90-2 HCAPLUS
CN 2,4-Pentadienamide, 2-cyano-5-(4-hydroxy-3,5-dimethoxyphenyl)-N-(2-hydroxyethyl)-, (2E,4E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 368836-91-3 HCAPLUS
CN 2,4-Pentadienamide, 2-cyano-5-(4-nitrophenyl)-N-(phenylmethyl)-, (2E,4E)-(9CI) (CA INDEX NAME)

Double bond geometry as shown.



IT **368836-71-9P 368836-75-3P 368836-77-5P**

368836-88-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of styrylacrylonitriles useful in treating a variety of **cell proliferative** disorders such as **cancer**
)

RN 368836-71-9 HCAPLUS
CN 2,4-Pentadienamide, 2-cyano-5-(3,4-dimethoxyphenyl)-N-(phenylmethyl)-, (2E,4E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 368836-75-3 HCAPLUS
CN 2,4-Pentadienamide, 5-[3,4-bis[[(1,1-dimethylethyl)dimethylsilyl]oxy]phenyl]-2-cyano-N-(phenylmethyl)-, (2E,4E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 368836-77-5 HCAPLUS
CN 2,4-Pentadienamide, 5-[3,4-bis[[(1,1-dimethylethyl)dimethylsilyl]oxy]phenyl]-2-cyano-N-[(3,4-dihydroxyphenyl)methyl]-, (2E,4E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 368836-88-8 HCAPLUS
CN 2,4-Pentadienamide, 5-[3,4-bis[[(1,1-dimethylethyl)dimethylsilyl]oxy]phenyl]-2-cyano-, (2E,4E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



IT **368836-79-7P 368836-80-0P 368836-81-1P**
368836-82-2P 368836-83-3P 368836-84-4P
368836-85-5P 368836-86-6P 368836-87-7P
368836-92-4P 368836-93-5P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of styrylacrylonitriles useful in treating a variety of **cell proliferative** disorders such as **cancer**
)

RN 368836-79-7 HCAPLUS
CN 2,4-Pentadienamide, 2-cyano-5-phenyl-N-(phenylmethyl)-, (2E,4E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 368836-80-0 HCAPLUS
CN 2,4-Pentadienamide, 2-cyano-5-(4-hydroxy-3,5-dimethoxyphenyl)-N-(phenylmethyl)-, (2E,4E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 368836-81-1 HCAPLUS

CN 2,4-Pentadienamide, 2-cyano-5-(3,4-dimethoxyphenyl)-N-(2-phenylethyl)-, (2E,4E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 368836-82-2 HCAPLUS
CN 2,4-Pentadienamide, 2-cyano-5-(4-hydroxy-3,5-dimethoxyphenyl)-N-(2-phenylethyl)-, (2E,4E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 368836-83-3 HCAPLUS
CN 2,4-Pentadienamide, 2-cyano-5-(4-hydroxy-3,5-dimethoxyphenyl)-N-(3-phenylpropyl)-, (2E,4E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 368836-84-4 HCAPLUS
CN 2,4-Pentadienethioamide, 2-cyano-5-(4-hydroxy-3,5-dimethoxyphenyl)-, (2E,4E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 368836-85-5 HCAPLUS
CN 2,4-Pentadienamide, 2-cyano-5-(4-hydroxy-3,5-dimethoxyphenyl)-, (2E,4E)-(9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 368836-86-6 HCAPLUS
CN 2,4-Pentadienoic acid, 2-cyano-5-(4-hydroxy-3,5-dimethoxyphenyl)-, (2E,4E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 368836-87-7 HCAPLUS
CN 2,4-Pentadienoic acid, 2-cyano-5-(4-hydroxy-3,5-dimethoxyphenyl)-, methyl ester, (2E,4E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 368836-92-4 HCAPLUS
CN 2,4-Pentadienamide, 2-cyano-N-[(3,4-dihydroxyphenyl)methyl]-5-(4-nitrophenyl)-, (2E,4E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 368836-93-5 HCAPLUS
CN 1,3,5-Hexatriene-1,1,3-tricarbonitrile, 2-amino-6-(4-nitrophenyl)-, (3Z,5E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L47 ANSWER 8 OF 11 HCAPLUS COPYRIGHT 2005 ACS on STN
AN 1995:782006 HCAPLUS
DN 123:179478
TI SSI tyrphostin pharmaceuticals.
IN Levitzki, Alexander; Novogrodsky, Abraham; Gazit, Aviv
PA Yissum Research Development Company, Israel; Kupot-Holim Health Insurance Institute
SO PCT Int. Appl., 47 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9514464	A1	19950601	WO 1994-US13535	19941123
	W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LT, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US, UZ, VN				
	RW: KE, MW, SD, SZ, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	IL 107736	A1	20010111	IL 1993-107736	19931124
	CA 2177289	AA	19950601	CA 1994-2177289	19941123
	AU 9512935	A1	19950613	AU 1995-12935	19941123
	AU 702800	B2	19990304		
	EP 731697	A1	19960918	EP 1995-904123	19941123
	EP 731697	B1	20010418		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	JP 10504014	T2	19980414	JP 1994-515214	19941123

AT 200618 E 20010515 AT 1995-904123 19941123
PRAI IL 1993-107736 A 19931124
WO 1994-US13535 W 19941123
OS MARPAT 123:179478
AB SSI tyrphostins are useful in preventing LPS-induced toxicity, TNFα-induced toxicity, LPS-induced increases in TNFα levels, nitric oxide production, and the treatment of septic shock and various immune disorders. A SSI tyrphostin was prepared by the condensation of 2-cyano-N-(3-phenylpropyl)acetamide with p-nitrobenzaldehyde in the presence of β-alanine in EtOH. The effectiveness of the tyrphostin in preventing lipopolysaccharide-induced toxicity was demonstrated in mice.
IC ICM A61K031-165
ICS A61K031-275
CC 63-6 (**Pharmaceuticals**)
Section cross-reference(s): 1, 25
IT 10537-47-0P 60951-74-8P 90947-89-0P 101756-38-1P 116313-73-6P 118409-56-6P 118409-57-7P 118409-62-4P 158069-71-7P 167493-14-3P 167493-15-4P 167493-16-5P 167493-17-6P 167493-18-7P 167493-19-8P 167493-20-1P 167493-21-2P 167493-22-3P 167493-23-4P 167493-24-5P **167493-25-6P** 167493-26-7P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)
(SSI tyrphostin pharmaceuticals for treatment of immune disorders LPS-induced toxicity prevention)
IT **167493-25-6P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)
(SSI tyrphostin pharmaceuticals for treatment of immune disorders LPS-induced toxicity prevention)
RN 167493-25-6 HCAPLUS
CN 2,4-Pentadienamide, 2-cyano-5-(3-hydroxy-4-nitrophenyl)-N-(3-phenylpropyl)- (9CI) (CA INDEX NAME)



L47 ANSWER 9 OF 11 HCAPLUS COPYRIGHT 2005 ACS on STN
AN 1994:579571 HCAPLUS
DN 121:179571
TI preparation of isoxazole derivatives as lipoxygenase inhibitors
IN Suzuki, Masahiro; Nozaki, Kenzi; Hosoya, Toshiyuki; Suzuki, Takashi; Basaki, Yuzi; Kozima, Mitiyo; Matsuura, Naosuke
PA Taiho Pharmaceutical Co., Ltd., Japan
SO PCT Int. Appl., 105 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9410157	A1	19940511	WO 1993-JP1572	19931029
	W: AU, CA, KR, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	JP 06135948	A2	19940517	JP 1992-333429	19921030
	CA 2126972	AA	19940511	CA 1993-2126972	19931029
	CA 2126972	C	19971223		
	AU 9453450	A1	19940524	AU 1994-53450	19931029
	AU 671170	B2	19960815		
	EP 623603	A1	19941109	EP 1993-923667	19931029
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	US 5478856	A	19951226	US 1994-256058	19940627
PRAI	JP 1992-333429	A	19921030		
	WO 1993-JP1572	W	19931029		

OS MARPAT 121:179571

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Isoxazole derivs. [I; R1, R2 = H, alkyl, alkoxy, halo; R3 = OH. alkyl, alkoxy, acyl, etc.; X = bond, N(Z)CO (wherein Z = H, alkyl, carboxyalkyl, etc.); Y = (un)substituted CH:CH, CH:CHCH:CH; m, n = 0-5] are prepared and formulated. A mixture of isoxazole derivative II, cinnamic acid derivative III, 1-hydroxybenzotriazole, and DCC in DMF was stirred at room temperature to give 50.6% IV, which showed IC50 of 2.87 μM and 1.17 μM against cyclooxygenase and lipoxygenase, resp. Granular, tablet, capsule, injection, and syrup formulations were given.

IC ICM C07D261-08
ICS C07D261-14; C07D413-12; C07D413-14; A61K031-42; A61K031-44; A61K031-675

CC 28-6 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1, 63

IT 157724-49-7P 157724-50-0P 157724-51-1P 157724-52-2P 157724-53-3P
157724-54-4P 157724-55-5P 157724-56-6P 157724-57-7P 157724-58-8P
157724-59-9P 157724-60-2P 157724-61-3P 157724-62-4P
157724-63-5P 157724-64-6P 157724-65-7P 157724-66-8P 157724-67-9P
157724-68-0P 157724-69-1P 157724-70-4P 157724-71-5P 157724-72-6P
157724-73-7P 157724-74-8P 157724-75-9P 157724-76-0P 157724-77-1P
157724-78-2P 157724-79-3P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as lipoxygenase inhibitor)

IT **157724-59-9P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as lipoxygenase inhibitor)

RN 157724-59-9 HCAPLUS

CN 2,4-Pentadienamide, N-[2-[3,4-bis(4-methoxyphenyl)-5-isoxazolyl]ethyl]-2-cyano-5-(4-hydroxy-3,5-dimethoxyphenyl)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



L47 ANSWER 10 OF 11 HCAPLUS COPYRIGHT 2005 ACS on STN
AN 1994:54333 HCAPLUS
DN 120:54333
TI Preparation of sulfonamidoaryl hydroxamic acids as inflammation and tumor inhibitors
IN Ohtani, Mitsuaki; Arita, Hitoshi; Sugita, Kenji; Matsuura, Takaharu; Shirahase, Kazuhiro
PA Shionogi and Co., Ltd., Japan
SO PCT Int. Appl., 125 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9312075	A1	19930624	WO 1992-JP1593	19921207

W: JP, KR, US
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE

	EP 570594	A1	19931124	EP 1992-924883	19921207
	EP 570594	B1	19970730		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, MC, NL, PT, SE				
	AT 156116	E	19970815	AT 1992-924883	19921207
	ES 2107557	T3	19971201	ES 1992-924883	19921207
	JP 3342485	B2	20021111	JP 1993-510775	19921207
	US 5534654	A	19960709	US 1993-98272	19930803
PRAI	JP 1991-350793	A	19911210		
	WO 1992-JP1593	W	19921207		

OS MARPAT 120:54333

GI

Q= 



II



III

AB The title compds. R2ONR1COXA1YNR3BA2 (I) [A1 = (substituted) aromatic ring, aromatic heterocyclic ring; A2 = H, (substituted) aryl, aromatic heterocyclic ring; B = single bond, B1B2; B1 = CO, SO2; B2 = alkylene, alkenylene, etc.; X = (substituted) alkylene which may have O, S, N and may have unsatd. bond; Y = single bond, heteroatom, (substituted) alkylene which may contain heteroatom and may have unsatd. bond; X and N (which is linked to Y) may together form a moiety Q; R1 - R3 = H, (substituted) alkyl, aryl] were prepared I inhibit hemangioendothelial cell growth, the development of a lymphocyte adhesion factor, and ras gene-induced cell transformation and are useful as inflammation and tumor inhibitors. Condensation of carboxylic acid (E)-II (R = OH) with NH2OH.HCl in DMF containing N-hydroxysuccinimide, N,N-dicyclohexylcarbodiimide, and Et3n gave (E)-II (R = NHOH). Hydroxamic acid (E)-III in vitro exhibited MIC of 0.039 μM against ras gene-induced cell transformation.

IC ICM C07C259-06
ICS C07C311-08; C07C311-21; C07D209-18; A61K031-16; A61K031-40

CC 25-19 (Benzene, Its Derivatives, and Condensed Benzenoid Compounds)
Section cross-reference(s): 1

IT Transformation, **neoplastic**
(of cells, ras gene induction of, aryl hydroxamic acid inhibition of)

IT **Cell proliferation**
(of endothelium, aryl hydroxamic acid inhibition of)

IT Inflammation inhibitors
Neoplasm inhibitors
(sulfonamidoaryl hydroxamic acids)

IT 21226-31-3P 30461-77-9P 33832-98-3P 34837-67-7P 73282-11-8P
80360-23-2P 89113-18-8P 90312-03-1P 92851-56-4P 117379-58-5P
129866-23-5P 143390-49-2P 151720-48-8P 151720-64-8P 151720-65-9P
151720-66-0P 151720-67-1P 151720-68-2P 151720-69-3P 151720-70-6P
151720-71-7P 151720-72-8P 151720-73-9P 151720-74-0P
151720-75-1P 151720-76-2P 151720-77-3P 151720-78-4P 151720-79-5P
151720-80-8P 151720-81-9P 151720-82-0P 151720-83-1P 151720-84-2P

151720-85-3P 151720-86-4P 151720-87-5P 151720-88-6P 151720-89-7P
151720-90-0P 151720-91-1P 151720-92-2P 151720-93-3P 151720-94-4P
151720-95-5P 151720-96-6P 151720-97-7P 151720-98-8P 151720-99-9P
151721-00-5P 151721-01-6P 151721-02-7P 151721-03-8P 151721-04-9P
151721-05-0P 151721-06-1P 151721-07-2P 151721-08-3P 151721-09-4P
151721-10-7P 151721-11-8P 151721-12-9P 151721-13-0P 151721-14-1P
151721-15-2P 151721-16-3P 151721-17-4P 151721-18-5P 151721-19-6P
151721-20-9P 151721-21-0P 151721-22-1P 151721-23-2P 151721-24-3P
151721-25-4P 151721-26-5P 151721-27-6P 151721-28-7P 151721-29-8P
151721-30-1P 151721-31-2P 151721-32-3P 151721-33-4P 151721-34-5P
151721-35-6P 151721-36-7P 151721-37-8P 151721-38-9P 151721-39-0P
151721-40-3P 151721-41-4P 151721-42-5P 151721-43-6P 151721-44-7P
151721-45-8P 151721-46-9P 151721-47-0P 151721-48-1P 151721-49-2P
151721-50-5P 151721-51-6P 151721-52-7P 151721-53-8P 151721-54-9P
151721-55-0P 151721-56-1P 151721-57-2P 151721-58-3P 151721-59-4P
151721-60-7P 151721-61-8P 152016-52-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reaction of, in preparation of inflammation and tumor inhibitor)

IT 151720-27-3P 151720-28-4P 151720-29-5P 151720-30-8P 151720-31-9P
151720-32-0P 151720-33-1P **151720-34-2P** 151720-35-3P
151720-36-4P 151720-37-5P 151720-38-6P 151720-39-7P 151720-40-0P
151720-41-1P 151720-42-2P 151720-43-3P 151720-44-4P 151720-45-5P
151720-46-6P 151720-47-7P 151720-49-9P 151720-50-2P 151720-51-3P
151720-52-4P 151720-53-5P 151720-54-6P 151720-55-7P 151720-56-8P
151720-57-9P 151720-58-0P 151720-59-1P 151720-60-4P 151720-61-5P
152016-50-7P 153118-62-8P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as inflammation and tumor inhibitor)

IT **151720-71-7P 151720-72-8P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reaction of, in preparation of inflammation and tumor inhibitor)

RN 151720-71-7 HCAPLUS
CN 2,4-Pentadienoic acid, 2-cyano-5-[2-[(phenylsulfonyl)amino]phenyl]-, (E,E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 151720-72-8 HCAPLUS
CN 2,4-Pentadienoic acid, 2-cyano-5-[2-[(phenylsulfonyl)amino]phenyl]-, ethyl ester, (E,E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



IT **151720-34-2P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as inflammation and tumor inhibitor)
RN 151720-34-2 HCAPLUS
CN 2,4-Pentadienamide, 2-cyano-N-hydroxy-5-[2-[(phenylsulfonyl)amino]phenyl]-, (E,E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L47 ANSWER 11 OF 11 HCAPLUS COPYRIGHT 2005 ACS on STN
AN 1991:49360 HCAPLUS
DN 114:49360
TI Ultraviolet radiation absorbing compositions
IN Phalangas, Charalambos J.; Restaino, Alfred J.; Yang, Lau S.
PA ICI Americas, Inc., USA
SO U.S., 9 pp.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 4950467	A	19900821	US 1986-930523	19861114
PRAI US 1986-930523		19861114		

OS MARPAT 114:49360
AB Sunscreen compns. are described, which contain 5-phenylpentadienoate esters which act as UV filters when incorporated in a carrier in amts. ranging from 0.1-50% by weight The Markush structures of 5-phenylpentadienoate esters are described. The compns. of 16 sunscreens are given and 21 esters prepared
IC ICM A61K007-40
ICS A61K007-42; A61K007-44; A61K031-74
INCL 424059000
CC 62-4 (Essential Oils and Cosmetics)
Section cross-reference(s): 25
IT 1552-95-0P, Ethyl 5-phenyl-2,4-pentadienoate 6943-03-9P

24139-56-8P, Ethyl 2-cyano-5-phenyl-2,4-pentadienoate
92251-53-1P, Ethyl 2-methyl-5-phenyl-2,4-pentadienoate 95937-30-7P
131512-67-9P 131512-68-0P 131512-69-1P 131512-70-4P 131512-71-5P
131512-73-7P, Ethyl 2-ethyl-5-phenyl-2,4-pentadienoate
131512-74-8P 131512-75-9P, Isoamyl 2-cyano-5-phenyl-2,4-pentadienoate 131512-76-0P, Ethyl 2,4-dimethyl-5-phenyl-2,4-pentadienoate 131512-78-2P 131512-79-3P, Ethyl 2-butyl-5-phenyl-2,4-pentadienoate **131512-80-6P 131512-81-7P**, Amyl 2-cyano-5-phenyl-2,4-pentadienoate
RL: **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as sunscreen)

IT **24139-56-8P**, Ethyl 2-cyano-5-phenyl-2,4-pentadienoate
131512-74-8P 131512-75-9P, Isoamyl 2-cyano-5-phenyl-2,4-pentadienoate **131512-80-6P 131512-81-7P**, Amyl 2-cyano-5-phenyl-2,4-pentadienoate
RL: **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as sunscreen)

RN 24139-56-8 HCAPLUS
CN 2,4-Pentadienoic acid, 2-cyano-5-phenyl-, ethyl ester (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)



RN 131512-74-8 HCAPLUS
CN 2,4-Pentadienoic acid, 2-cyano-5-phenyl-, 2-ethylhexyl ester (9CI) (CA INDEX NAME)



RN 131512-75-9 HCAPLUS
CN 2,4-Pentadienoic acid, 2-cyano-5-phenyl-, 3-methylbutyl ester (9CI) (CA INDEX NAME)



RN 131512-80-6 HCAPLUS
CN 2,4-Pentadienoic acid, 2-cyano-5-[4-(1,1-dimethylethyl)phenyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 131512-81-7 HCAPLUS
CN 2,4-Pentadienoic acid, 2-cyano-5-phenyl-, pentyl ester (9CI) (CA INDEX NAME)



=>